Harmos Horton Lusk is pleased to have advised NZX/ASX listed Pacific Edge Limited on its NZ$36.1 million equity capital raise by way of placement and retail offer, launched on 11 May 2026. The placement received strong support from existing and new investors, and was upsized with board approval from NZ$18 million to NZ$25.4 million. The retail offer was similarly well-supported by the company’s shareholders, raising NZ$10.7 million of additional equity capital (including NZ$4.7 million of oversubscriptions).
Pacific Edge is a global cancer diagnostics company leading the way in the development and commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. With the new capital raised under the placement and retail offer, Pacific Edge has begun seeking claim-by-claim Medicare reimbursement for its Cxbladder Triage and Triage Plus tests, pursuant to a new draft Local Coverage Determination establishing hematuria evaluation as a covered Medicare benefit for the first time.
The Harmos Horton Lusk team that advised on the transaction was led by directors Nathanael Starrenburg and Tim Mitchelson, and included associates Kelsey Haub and Sam Baker and law clerk Jacob Rackham.
< Back